ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Thunnissen, E.; Lissenberg-Witte, B.; van den Heuvel, M.; Monkhorst, K.; Skov, B.; Sorensen, J.; Mellemgaard, A.; Dingemans, A.; Speel, E.; de Langen, A.; Hashemi, S.; Bahce, I; van der Drift, M.; Looijen-Salamon, M.; Gosney, J.; Postmus, P.; Samii, S.; Duplaquet, F.; Weynand, B.; Durando, X.; Penault-Llorca, F.; Finn, S.; Grady, A.; Oz, AYŞİM; Akyurek, N.; Buettner, R.; Wolf, J.; Bubendorf, L.; Duin, S.; Marondel, I; Heukamp, L.; Timens, W.; Schuuring, E.; Pauwels, P.; Smit, E.

doi:10.1016/j.lungcan.2019.09.023

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Thunnissen E., Lissenberg-Witte B., van den Heuvel M. M., Monkhorst K., Skov B. G., Sorensen J. B., ...More

LUNG CANCER, vol.138, pp.13-18, 2019 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 138
Publication Date: 2019
Doi Number: 10.1016/j.lungcan.2019.09.023
Journal Name: LUNG CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.13-18
Istanbul University-Cerrahpasa Affiliated: No

Abstract

Objective: Metastasized non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) rearrangement is usually sensitive to a range of ALK-tyrosine kinase inhibitors. ALK-positive NSCLC have been identified in pivotal phase III trials with fluorescence in situ hybridization (ALK FISH +). These tumors are also expressing the fusion product (ALK immunohistochemistry (IHC) +). However, discrepant cases occur, including ALK IHC + FISH-. The aim of this study was to collect ALK IHC + cases and compare within this group response to crizotinib treatment of ALK FISH + cases with ALK FISH- cases.